2026-05-19T04:36:35Zhttps://keep.lib.asu.edu/oai/request

oai:keep.lib.asu.edu:node-2004342025-04-18T19:29:49Zoai_pmh:repo_items

200434 https://hdl.handle.net/2286/R.2.N.200434 http://rightsstatements.org/vocab/InC/1.0/ http://creativecommons.org/licenses/by-nc-sa/4.0 2025-05 2026-04-18T05:00:00 28 pages Brar, Akarshi Rahman, Masmudur Carmona, Jacqueline Barrett, The Honors College School of Life Sciences Oncolytic Virotherapy describes using viruses to kill cancer cells in a targeted fashion. One example of an Oncolytic virus is Myxoma Virus (MYXV), a poxvirus that can kill certain cancer cells, while keeping healthy cells intact. However, it is not 100% effective in killing all types of cancer. One possible way to improve MYXV’s ability to kill cancer cells is using combination therapy, where MYXV and additional drugs are combined into one treatment. One drug of interest is Selinexor, which inhibits nuclear exporter protein XPO1/CRM1, potentially impacting MYXV’s replication cycle. In this project, we seek to understand how to maximize MYXV’s ability to kill cancer cells when combined with Selinexor as well as to determine how, even with combination therapy, some cancer cells still evade treatment. To do so, colony forming assays and viral titrations were completed. Colony forming assays were performed in PANC-1 cells. From the assays, we found that cells that underwent treatment with Selinexor and Wild Type MYXV had increased amounts of cell death and reduced amounts of treatment evasion in comparison to cells that did not undergo the combination therapy. Additionally, titrations were used to determine Selinexor’s impacts on MYXV variants, specifically vMyx-M11L-KO which lacks expression of the antiapoptotic gene M11L. Titrations were completed in LLC1 cells. From these experiments, we found that Selinexor significantly improved the ability of the virus to replicate. Overall, our results show that combination therapy of MYXV with Selinexor has a promising impact on cancer cell treatment. Cancer Immunotherapy Myxoma virus Selinexor Oncolytic Virotherapy Evaluating the Effect of Combination Therapy Using Myxoma Virus (MYXV) and Selinexor on Cancer Cells In Vitro